Lupin subsidiary signs exclusive license for YUVEZZI eye drop in Europe

Strategic Transactions View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹2225.00

prior close

₹2230.40

announcement price

In-mkt

timing

Nifty Midcap 150market+0.4%-1.4% vs market

Pharmaceuticals peers, median of 173sector+0.2%-1.3% vs sector

On the reaction day the stock moved 1.4 pts less than Nifty Midcap 150 and 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.3

15m

-0.4

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1+0.4-1.4+0.2-1.3

Next day

-1.0+0.4-1.5+0.4-1.5

-1.8+0.5-2.3+0.4-2.2

-2.4+1.0-3.4+0.0-2.4

-1.2+1.0-2.2+0.8-2.0

-2.6+0.9-3.4+0.6-3.2

-1.6+1.0-2.6+1.6-3.2

15d

-6.6-1.7-4.9+2.2-8.8

-4.5-2.1-2.4+3.2-7.7

-11.7-9.0-2.7-4.1-7.7

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin's Dutch subsidiary VISUfarma signed an exclusive license deal with US-based Visus Therapeutics to commercialize YUVEZZI, an FDA-approved eye drop for presbyopia (age-related near vision loss), across EU, UK, Switzerland, Norway and Iceland. Deal worth up to 75 million euros: 20 million equity investment via SAFE plus 55 million in milestones, plus royalties on sales. Agreement runs 20 years from first launch. Not a related party transaction.

Likely market impact

Positive for Lupin. Strengthens specialty ophthalmology portfolio in Europe with a differentiated, approved product. Long-term revenue via royalties and milestones.